Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) were up 6.1% during mid-day trading on Monday . The company traded as high as $4.56 and last traded at $4.55, with a volume of 763,169 shares changing hands. The stock had previously closed at $4.29.

A number of analysts have recently issued reports on KERX shares. FBR & Co reiterated a “buy” rating and set a $13.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Monday, July 25th. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Wednesday, July 13th. Maxim Group reiterated a “buy” rating and set a $9.00 price objective (up previously from $7.00) on shares of Keryx Biopharmaceuticals in a research note on Friday, July 8th. Ladenburg Thalmann lifted their price objective on shares of Keryx Biopharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Finally, Morgan Stanley reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research note on Saturday, April 30th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.75.

The company’s market capitalization is $463.82 million. The stock has a 50 day moving average price of $6.17 and a 200 day moving average price of $5.27.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.14. The firm earned $9.30 million during the quarter, compared to the consensus estimate of $8.60 million. Keryx Biopharmaceuticals’s revenue for the quarter was up 272.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.26) EPS. Equities research analysts expect that Keryx Biopharmaceuticals Inc. will post ($1.23) EPS for the current year.

In related news, CFO Scott A. Holmes sold 4,935 shares of the business’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $7.36, for a total value of $36,321.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

A hedge fund recently bought a new stake in Keryx Biopharmaceuticals stock. Royce & Associates LLC purchased a new stake in shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned 0.32% of Keryx Biopharmaceuticals at the end of the most recent reporting period.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.